VX-809

inquiry

Cat No.

CEI-0253

Description

VX-809 can inhibit CFTR with IC 50 of 100 nM.

CAS_No

936727-05-8

Molecular Weight

452.41

Purity

>99%

Storage

2 years at -20centigrade Powder

Targets

CFTR

Molecular Formula

C24H18F2N2O5

Chemical Name

3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

Solubility

DMSO 91 mg/mL Water

In vitro

VX-809 is a CFTR corrector that was advanced into clinical development for the treatment of cystic fibrosis. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC(50), 81 +/- 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability.

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry